Research on new insulins
Marcus Schindler, head of research at Danish pharmaceutical company Novo Nordisk, talks about the current state of research into new insulins, cardiovascular activities and the financial viability of high-cost innovations.
Marcus Schindler, head of research at Danish pharmaceutical company Novo Nordisk, talks about the current state of research into new insulins, cardiovascular activities and the financial viability of high-cost innovations.